My cancer and research specialty is multiple myeloma. Myeloma–and most of the blood cancers, for that matter–are seeing an explosion of drugs which are extending median life expectancies of patients. Some only potentially add a few months of life–others years. All are expensive and experimental.

Thursday I wrote a long article about the upcoming American Society of Clinical Oncology (ASCO) annual meeting and convention in Chicago. I will be attending the event, writing a daily report for The Myeloma Beacon. I will also be blogging several times each day here, as well as my other site, www.MultipleMyelomaBlog.com.

Once you are on approved press roster, you begin to recieve a lot of ASCO related research “teasers.” These pre-releases of information are released by drug companies to build excitement and anticipation over research results which will be presented at ASCO.

I won’t post all of these releases. Frankly, I just don’t have the time–and some have more relevance to cancer patients than others. Many of these reports are released for investors and business publications, not patients.

The size and scope of this flood of info can be overwhelming. There are over 1.4 million cancer patients diagnosed in the United States each year, with over 200 different types of cancer. Too much for one sick guy to cover!

I will be screening these reports for those of you who don’t have the time to read page after page after page of research data. I will post a few I feel are most relevant for us–the patients and survivors and caregivers.
Keeping all of this in mind, here is an example of the many pre-meeting articles about the upcomming event I will be receiving daily:

Nexavar Data To Be Presented at 46th American Society of Clinical Oncology Annual Meeting

Berlin, May 21, 2010 – Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. today announced that more than 70 studies evaluating the use of Nexavar® (sorafenib) tablets will be presented at the 2010 American Society of Clinical Oncology (ASCO) annual meeting, June 4-8, 2010, in Chicago, IL.

“Bayer and Onyx are encouraged by the number and breadth of studies involving Nexavar that are being presented at ASCO,” said Dimitris Voliotis, vice president, Global Clinical Development Oncology, Bayer HealthCare. “We have built a strong foundation with Nexavar in the treatment of patients with unresectable liver cancer and advanced kidney cancer and are committed to continuing research across tumor types and in a variety of treatment settings to determine the full potential of this therapy for cancer patients.”

Nexavar data highlights include:

Hepatocellular Carcinoma (HCC) • Sorafenib or Placebo in Combination with Transarterial Chemoembolization (TACE) for Intermediate-Stage Hepatocellular Carcinoma (SPACE) o Professor Riccardo Lencioni, Division of Diagnostic and Interventional Radiology, Cisanello University Hospital, Pisa, Italy o Abstract TPS178, Trials in Progress Poster Session, Clinical Trials Special Session o Monday, June 7, 2010, 8:00 a.m.-12:00 p.m., S Hall A2

• Efficacy and Safety of Sorafenib in Patients with Advanced Hepatocellular Carcinoma; Subgroup Analysis of the SHARP Trial by Baseline Transaminase (ALT/AST)/? alpha-Fetoprotein (AFP) and Bilirubin Levels o Jean-Luc Raoul, M.D., PhD, Centre Eugene Marquis, Rennes, France o Abstract 4051, General Poster Session, Gastrointestinal (Noncolorectal) Cancer Track o Sunday, June 6, 2010, 2:00-6:00 p.m., S Hall A2

Renal Cell Carcinoma (RCC) • Long-term Sorafenib Safety Profile in More Than 700 Patients with Renal-Cell Carcinoma Treated for 12 to 42 Months o Thomas E. Hutson, DO, PharmD, FACP Texas Oncology, PA, Baylor Sammons Cancer Center, Baylor University Medical Center Dallas, Texas o Abstract 4614, General Poster Session, Genitourinary Cancer Track o Monday, June 7, 2010, 1:00-5:00 p.m., S Hall A2

Lung Cancer • Sorafenib Treatment Efficacy and KRAS Biomarker Status in the Biomarker-Integrated Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) trial. o Roy Herbst, M.D., Ph.D., Department of Thoracic/Head and Neck Medical Oncology, MD Anderson Cancer Center, Houston, Texas o Abstract 7609, General Poster Session, Lung Cancer – Metastatic Track o Sunday, June 6, 2010, 8:00 a.m.-12:00 p.m., S Hall A2

Breast Cancer • Multivariate Analysis (MVA) of Progression-Free Survival (PFS) in 2 Phase 2b, Multinational, Double-Blind, Randomized, Placebo-Controlled Trials Evaluating Sorafenib Plus Standard Chemotherapy in Patients with HER-2 Negative Locally advanced or Metastatic Breast Cancer. o William John Gradishar, M.D., Northwestern University Feinberg School of Medicine, Chicago, Illinois o Abstract 1073, General Poster Session, Breast Cancer Track o Saturday, June 5, 2010, 2:00-6:00 p.m., S Hall A2

• A Regional Subgroup Analysis of a Multinational, Double-Blind, Randomized, Placebo Controlled, Phase 2b Study Evaluating Sorafenib (SOR) with Paclitaxel (PAC) in Patients (pts) with Advanced Breast Cancer (BC). o Tarini Prasad Sahoo, M.D., Jawaharlal Nehru Cancer Hospital & Research Centre, Bhopal, India o Abstract 1114, General Poster Session, Breast Cancer Track o Saturday, June 5, 2010, 2:00-6:00 p.m., S Hall A2

• Management of Hand-Foot Skin Reaction (HFSR)/Hand-Foot Syndrome (HFS) in SOLTI-0701: A Double-Blind, Randomized Phase 2b Study Comparing Sorafenib vs Placebo in Combination with Capecitabine in Patients with Advanced Breast Cancer. o Patricia Gomez, M.D., Breast Cancer Center, Vall d’Hebron University Hospital, Barcelona, Spain o Abstract 1083, General Poster Session, Breast Cancer Track o Saturday, June 5, 2010, 2:00-6:00 p.m., S Hall A2

“With more than 70 investigator and company sponsored studies being presented at ASCO, we look forward to continuing our work with investigators to understand how Nexavar may fit into other areas of the therapeutic landscape, particularly with respect to how biomarkers status may guide selection of therapy, which is a step toward personalized medicine,” said Ted W. Love, M.D., Executive Vice President and Head of Research and Development at Onyx Pharmaceuticals.

Wow! Talk about throwing a lot against the wall to see what sticks! It isn’t fun to read through all of these–even for me! But there is a lot of important info here. Nexavar research is progressing on a number of fronts: lung cancer, liver cancer, kidney cancer, breast cancer–most any solid tumor related cancer. It is even being researched to see if it will work in any of the blood cancers.

My job is to screen these releases to find the most promising results, so I can attend those specific meetings and ask questions and get a feel for what might help us cancer patients most–and most quickly.

Feel good and keep smiling! Pat

One thought on “Here It Comes! Early Teaser Releases Of The Most Promising New Cancer Drugs To Be Featured At ASCO. First Up: Nexavar

  1. Wow! And that is just teaser info. Now I know I need to pray hard and send positive thoughts to you. I am overwhelmed at what you are attempting to do for us patients. You KEEP smiling and feel good through this. Rest every chance you get.

    Rebecca and Jerry Weber

Leave a Reply